WHO confirmed that if any person experiences blood clotting after the first dose of the vaccines then he or she must withhold from taking the second dose. In an ‘interim guidance’ issued by WHO, it says, “More data have been obtained on the effectiveness of the vaccines in different population groups, such as older adults, making the evidence base more robust…A history of anaphylaxis to any component of the vaccine is a contraindication to vaccination”.
WHO Earlier Stated That the Efficacy of AstraZeneca is 100%
A global advisory committee of WHO stated earlier that the AstraZeneca vaccine is 79% efficient in dealing with the symptoms of coronavirus and 100% effective in preventing hospitalization followed by the death of the affected individuals. This data proved that the AstraZeneca vaccines are effective and safe. However, on its latest circular, WHO supported by SAGE experts recommend that if people face blood clotting issue after the first dose of AstraZeneca, then they must withhold from taking the second dose.
Platelet Count also Deteriorates besides Blood Clotting, in Rare Conditions
Not only does the blood clot, but the platelet counts also decrease in “very rare” conditions, said the WHO experts. And such a condition comes into effect within 4-20 days of taking the first dose. This condition is known as thrombosis with a TTS (thrombocytopenia syndrome). A statement from the experts says, “It is currently unknown whether there is a risk of TTS following the second dose. As data from additional studies become available, enabling a better understanding of the pathophysiology of TTS and its relationship to the vaccine, recommendations on vaccination will be updated, if appropriate. People who have had blood clots associated with low platelet levels (TTS) after their first dose should not be given their second dose”.
Geographic Variation Lowers the Risk of TTS
As the AstraZeneca vaccine is widely used in various countries across varied geographical orientations, the survey experts found that it differs in its efficacy in different regions. Also, the range of such blood clotting cases and their impact is less seen in non-European countries. “An estimation of the risk outside Europe needs further data collection and analysis. Data from the United Kingdom (31 March 2021) suggest the risk of TTS is approximately 4 cases per 1 million (1 case per 250 000) vaccinated adults, while the rate is estimated to be approximately 1 case per 100 000 in the EU. Current data from Europe suggest that the risk may be higher in younger adults compared with older adults; no specific risk factors have yet been identified”, suggest the report. But even though the vaccine is available for the virus, positive cases refuse to die down. We must be very careful and maintain the covid protocols strictly.